Skip to main content
. 2017 Jul 29;54(11):781–786. doi: 10.1136/jmedgenet-2017-104826

Figure 4.

Figure 4

(A) Change in volume fraction of GL3 inclusions/podocyte (∆Vv(Inc/PC)) and change in plasma lyso-Gb3 at baseline and after 6 months of migalastat treatment in patients with Fabry disease. (B) Change in volume of GL3 inclusions/podocyte (∆V(Inc/PC)) and change in plasma lyso-Gb3 at baseline and after 6 months of migalastat treatment in patients with Fabry disease. GL3, globotriaosylceramide.